DeepMed Research

EISAI LIMITED

🇮🇪Ireland

Country: 🇮🇪Ireland

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology

Active, not recruiting

Conditions: Alzheimer's Disease

Interventions: Other: No Intervention

First Posted Date: 2023-09-21

Last Posted Date: 2024-12-03

Lead Sponsor: Eisai Limited

Target Recruit Count: 2000

Registration Number: NCT06043700

Locations: 🇺🇸
Eisai Site #3, Clermont, Florida, United States
🇺🇸
Eisai Site #1, Lady Lake, Florida, United States
🇺🇸
Eisai Site #2, District Heights, Maryland, United States

A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: E7386 Tablet
Drug: (14C)E7386 Capsule
Drug: (14C)E7386

First Posted Date: 2022-11-07

Last Posted Date: 2023-09-21

Lead Sponsor: Eisai Limited

Target Recruit Count: 15

Registration Number: NCT05607537

Locations: 🇬🇧
Labcorp Clinical Research Unit, Leeds, United Kingdom

A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants

Phase 1

Withdrawn

Conditions: Healthy Volunteers

Interventions: Drug: E7386

First Posted Date: 2021-04-12

Last Posted Date: 2023-11-24

Lead Sponsor: Eisai Limited

Registration Number: NCT04840927

Locations: 🇬🇧
Quotient Sciences, Nottingham, United Kingdom

A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: [14C]E7090

First Posted Date: 2020-07-30

Last Posted Date: 2021-02-04

Lead Sponsor: Eisai Limited

Target Recruit Count: 8

Registration Number: NCT04493255

Locations: 🇬🇧
Covance Clinical Research Unit, Leeds, United Kingdom

A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures

Completed

Conditions: Partial Seizures

Interventions: Drug: Perampanel

First Posted Date: 2020-02-06

Last Posted Date: 2020-02-06

Lead Sponsor: Eisai Limited

Target Recruit Count: 243

Registration Number: NCT04257604

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Completed

Conditions: Generalised Tonic-Clonic Seizures
Idiopathic Generalized Epilepsy
Partial Onset Seizures

Interventions: Drug: Perampanel

First Posted Date: 2020-02-05

Last Posted Date: 2023-02-09

Lead Sponsor: Eisai Limited

Target Recruit Count: 191

Registration Number: NCT04252846

Locations: 🇮🇹
Fondazione PTV Policlinico Tor Vergata, Roma, Lazio, Italy
🇷🇺
Krasnoyarsk State Medical University n.a. V.F. Voyno-Ysenetskiy, Krasnoyarsk, Russian Federation
🇷🇺
City Clinical Hospital #1 n.a. N.I.Pirogov, Moscow, Russian Federation

and more 33 locations

To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Tumor

Interventions: Drug: Eribulin mesylate
Drug: Rifampicin

First Posted Date: 2016-12-23

Last Posted Date: 2017-03-15

Lead Sponsor: Eisai Limited

Target Recruit Count: 14

Registration Number: NCT03002493

Locations: 🇳🇱
Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱
University Medical Center Utrecht, Utrecht, Netherlands

Extended Treatment in Metastatic Breast Cancer With Eribulin

Completed

Conditions: Breast Cancer

First Posted Date: 2016-05-11

Last Posted Date: 2023-07-24

Lead Sponsor: Eisai Limited

Target Recruit Count: 45

Registration Number: NCT02769364

Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: E7050

First Posted Date: 2015-08-26

Last Posted Date: 2015-11-20

Lead Sponsor: Eisai Limited

Target Recruit Count: 42

Registration Number: NCT02533102

Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry

Completed

Conditions: Breast Cancer

First Posted Date: 2015-05-13

Last Posted Date: 2016-04-15

Lead Sponsor: Eisai Limited

Target Recruit Count: 77

Registration Number: NCT02443428

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy